Author Archives: admin


Combined adipose-derived mesenchymal stem cell and antibiotic … – Nature.com

Bacteria and biofilm formation

MSSA strain ATCC29213 (American Type Culture Collection, Manassas, VA, USA) was used as it tends to form biofilms32,33. MSSA was streaked onto plates containing tryptic soy broth and Bacto agar (BD Biosciences, Franklin Lakes, NJ, USA) and grown overnight in 5 mL of tryptic soy broth at 37 C in a shaking incubator. MSSA cells in the incubation medium were grown to the early exponential growth phase (0.20.3 optical density at 600 nm), corresponding to 5.0 107 CFU/mL.

Adipose tissue (~1.5 g) was obtained from Wistar rats (female; 12 weeks old; Japan SLC Corp., Shizuoka, Japan). ADSCs were prepared by modifying previously reported methods34. Further details can be found in the Supplementary file. Cellular characteristics (i.e. expression of stem cell surface markers) were determined using flow cytometric analysis after labeling ADSCs with appropriate antibodies of cultivation.

Wistar rats (female; 12 weeks old; Japan SLC Corp.) were housed under specific pathogen-free conditions with a 12-h light/dark cycle and ad libitum access to a certified diet (CRF-1; Oriental Yeast Corp., Tokyo, Japan) and water (chlorine concentration; 10 ppm). The drinking, feeding behavior, and body weight of the rats were monitored regularly. The animals were acclimatized for 7 days before undergoing the implant operation.

Rats were anesthetized with midazolam (2.5 mg/kg; Astellas Pharma, Tokyo, Japan), medetomidine (0.5 mg/kg; Zenoaq, Fukushima, Japan), and butorphanol tartrate (2.5 mg/kg; Meiji Seika Pharma, Tokyo, Japan). To establish infection, A medical-grade K-wire (1.2 mm diameter; Synthes Inc., West Chester, PA, USA) was incubated in an overnight culture with MSSA strain ATCC29213 and then air-dried for 20min prior to insertion. This MSSA strain exposure coats the screw with 5107 CFU. The K-wire was surgically placed into the distal femur as previously described34,35,36. Briefly, the skin overlying the leg was shaved and cleaned with iodine solution. A medial parapatellar approach was used, and the patella was dislocated laterally to access the knee joint. The femoral medullary canal was reamed with an 18-gauge needle and the K-wire was placed in a retrograde fashion with 1 mm of the wire protruding into the joint space. The quadriceps-patellar complex was reduced to the anatomic position, and the wound was closed with nylon 4-0 sutures. Rats were randomly assigned and equally divided into three groups: no-treatment, antibiotic (ciprofloxacin [3.0 mg/kg per day intravenously]), and ADSCs [5.0 105 cells intravenously 30 min, 6 h, and 18 h after the surgical procedure]) with antibiotic (ciprofloxacin [3.0 mg/kg per day intravenously] groups. The ADSC dose, based on a previous report37, is considered to not induce adverse effects, including a high mortality rate. Additionally, a previous report showed that a ciprofloxacin dose of 3.0 mg/kg per day caused no adverse effects or unstable conditions in rats11. MSSA induced infection in 100% of the untreated rats with no significant differences in the initial body weights between the different groups.

After evaluating the general overall condition and soft tissue swelling, the rats were euthanized on POD 14 using thiopental sodium (100 mg/kg body weight). Tissues from the knee joint space, femur, and implant were harvested in a sterile manner for ex vivo analyses.

Weight change (n = 6 rats per group) was calculated as a percentage change based on the preoperative weight to quantitatively measure the systemic response to infection. Preoperative baseline measurements were performed on the day before surgery. The weight of the rats was also evaluated on PODs 1, 3, 7, and 14.

Soft tissue and bone damage (n = 6 rats per group) on POD14 was scored by three examiners (D.I, A.T. and T.K.) blinded to the rats according to a modified Rissing scoring38,39. Further details can be found in Supplementary file.

CT imaging (n = 6 rats per group) was performed on POD14 to determine the degree of infection within the femoral region of interest. Considering that image artifacts from the K-wires may cause artifacts in the reconstructed CT images, isolated femurs from rats with the wire removed were subjected to CT scanning (LaTheta LCT-200; Hitachi Aloka Medical, Tokyo, Japan), operating at 50 kV and 0.5 mA (radiation exposure remained below 40 mSv). BMD was calculated automatically using LaTheta software (version 3.51). Reconstructed CT images were initially visualized in three dimensions (3D) to evaluate changes in bone morphology resulting from implant infection. A threshold-limited 3D rendering was created to visualize bone damage.

Implants were harvested (n = 6 rats per group) from each group. Based on a previous report, the bacterial burden on the implants was determined using a CFU assay40,41. To quantify living bacteria adherent to the implant within the biofilm, the removed implants were placed individually into 1.5-mL microtubes containing PBS (1 mL at 4C), vortexed for 15 s and sonicated for 5 min at 40 Hz in a water bath (Bransonic 5210; Branson Ultrasonics, Brookfield, CT, USA), followed by an additional 1 min of vortexing. The spread plate method was used to quantitatively evaluate the biofilm; the solution containing each bacterium from the biofilm was serially diluted 10-fold with PBS, followed by culturing on an agar plate at 37C for 24 h. MSSA was cultured on tryptic soy broth agar plates. The bacterial CFUs obtained from the implant were determined by counting the CFUs after culturing on plates overnight.

At the established endpoint (POD14), the femurs isolated from the rats were fixed in 10% neutralized formalin solution and dehydrated using an ethanol gradient (70%, 80%, 90%, and 100%). The fixed specimens were decalcified in 10% formic sodium citrate solution, embedded in paraffin, and sectioned in the coronal plane. The sections were stained with hematoxylin and eosin, and the slides were observed using an optical microscope (Biorevo BZ-9000; Keyence Corp., Osaka, Japan).

At the established endpoint (POD14), total RNA was extracted from the knee tissue of the rats (n = 6 rats per group). The mRNA expression of rCRAMP, TNF-, IL-6 and IL-1b was evaluated by quantitative PCR. All values were normalized to the level of the GAPDH gene, and relative gene expression levels were calculated using the 2Ct method42. Further details can be found in the Supplementary file (Supplementary Table S1).

Tissue sections were evaluated to determine the location of ADSCs following injection. To confirm the location of the injected ADSCs, they were labeled with the fluorescent dye DiI (Vybrant DiI Cell Labeling Solution; Life Technologies, Carlsbad, CA, USA) before injection. DiI binds to cellular thiols and has long-term stability, enabling the tracing of DiI-labeled transplanted cells in the host tissue. The concentration of ADSCs was adjusted to 5.0 105 cells/mL; DiI (5 L/mL) was dissolved in the cell culture media and incubated for 15 min at 37C in a 5% CO2 incubator for ADSCs labeling. The filtrate was centrifuged at 180g for 5 min at 25C and the supernatant was removed to separate the DiI from the filtrate. The ADSCs were centrifuged twice with Dulbeccos modified Eagle medium under the same conditions and the supernatant was removed. We used separate rats for this experiment (n = 3 rats per antibiotic group and DiI-labeled ADSCs with antibiotic group). On day 14 post-injection, a frozen section was prepared using Kawamotos film method in the sagittal plane43. For identification of tissues following DiI labeling, the gray-scale scale (16 bit) of the DiI-labeled section was used.

All continuous variables were assessed for normality using the ShapiroWilk test. Normally distributed data were expressed as the mean standard error. Data were analyzed using SPSS software (version 25.0; SPSS, Inc., Armonk, NY, USA). Multiple groups were compared using the Welch ANOVA followed by Tukey HSD or Games-Howell post-hoc test. For all analyses, results were considered statistically significant at p < 0.05.

The investigational protocol was approved by the Kanazawa University Advanced Science Research Centre (Approval Number: AP-194052), and all animals were treated in accordance with Kanazawa University Animal Experimentation Regulations. The study was carried out in compliance with the ARRIVE guidelines.

Visit link:
Combined adipose-derived mesenchymal stem cell and antibiotic ... - Nature.com

Global Cell Dissociation Solution Market to Reach USD 872.8 Million by 2030; Increasing R&D Activites in Emerg – openPR

The global cell dissociation solution market is expected to exhibit strong growth, reaching USD 872.8 million by 2030. As per the report titled "Cell dissociation solution Market Size, Share & COVID-19 Impact Analysis, By Type (Tissue Dissociation and Cell Detachment), By Product (Enzymatic Dissociation Products (Collagenase, Trypsin, Papain, Elastase, DNase, Hyaluronidase and Other Enzymes), Non-Enzymatic Dissociation Products and Instruments), By Tissue (Connective Tissues, Epithelial Tissues and Other Type Tissues (Skeletal and Muscles Tissues)), By End User (Pharmaceutical and Biotechnology Companies, Research and Academics and Other End Users), and Regional Forecasts, 2023-2030" observes that the market size in 2022 stood at USD 294.9 million and USD 872.8 million in 2030. The market is expected to exhibit a CAGR of 14.90% during the forecast period.

Get Free Sample @ https://marketsnresearch.com/sample/1660

Symphogen (Denmark) And Thermo Fisher Scientific Collaborated To Further Their Strategic Partnership

In 2020, to improve the discovery and development of biopharmaceuticals, Thermo Fisher Scientific extended its strategic partnership with Symphogen (Denmark). QIAGEN N.V. (Germany) was purchased by Thermo Fisher Scientific in order to increase the scope of its specialty diagnostics offering.

Increasing R&D Activites in Emerging Economies to Accelerate Market Growth

Players in the cell dissociation solutions market can expect to find significant growth prospects in emerging markets like China, India, and Brazil. The number of R&D initiatives in the life sciences sector has increased in these nations. For instance, Indian-based pharmaceutical companies are spending a lot of money on research and development to bring new medicines to market. An Indian pharmaceutical company named Cadila Healthcare Ltd. invested USD 113 million (or 13% more) in R&D in 2020 than it did in 2019. Similar to Biocon, another pharmaceutical business with headquarters in India, spent USD 58.79 million on R&D in 2020, a 52% increase from 2019. The country's demand for items involving cell dissociation solution is predicted to rise as a result of these investments.

Ethical Issues With Cell Biology Research To Constrain Business Expansion

Animals and humans must be employed in cell biology research because stem cell therapies and gene therapy studies that use gene recombination use both animal and human cells. In vivo drug toxicity and pharmacokinetic testing also uses these human and animal cells. This is due to the fact that direct testing on people or animals could be dangerous or even lethal. Furthermore, human embryos are often destroyed in stem cell research trials that employ them for medicinal purposes. In a number of nations around the world, strong restrictions have been developed by ethical authorities to regulate these operations. Cell biology research is being significantly constrained in many different countries due to these ethical issues and limitations on the use of cells for study.

Read More @ https://marketsnresearch.com/report/1660/global-cell-dissociation-solution-market

Major Players Develop Acquisition Plans to Boost Brand Image

The leading businesses in the cell dissociation solution market plan acquisitions to improve their brand recognition globally. For instance, in 2021, a definitive merger agreement between Roche Diagnostics and GenMark Diagnostics was signed in order to have access to cutting-edge technologies for testing several infections in a single patient sample.

Recent Development:In September 2022, Thermo Fisher unveiled the Orbitrap Ascend TriBrid last month at the International Mass Spectrometry Conference in Maastricht, Netherlands. This premium equipment is intended for proteomic and biopharma applications.List of Key Players Profiled in the ReportBDThermo Fisher Scientific Inc.F. Hoffmann-La Roche LtdGE HealthcareMerck KgaAATCCREPROCELL Inc.ALSTEMCellSystemsBIOCOM AGBiological Industries USA, Inc.PelobiotechBrainBits, LLCLabochemaHimedia LaboratoriesBIOCOMPAREPAN-BiotechGemini Bio-ProductsMiltenyi BiotecSTEMCELL Technologies, Inc.Cyagen Biosciences, Inc.PromoCell GmbHIrvine ScientificSigma-Aldrich Co. LLCOthers

Read More News

https://www.linkedin.com/pulse/cell-dissociation-solution-market-reach-usd-8728-million-vasa/?published=thttps://demo.sngine.com/blogs/183774/Cell-Dissociation-Solution-Market-Size-Type-Share-Demand-Drives-Growthhttps://www.benedeek.com/blogs/39503/Cell-Dissociation-Solution-Market-New-Investment-Growth-Opportunities-and-Analysishttps://www.gift-me.net/blogs/23581/Cell-Dissociation-Solution-Market-Global-Snapshot-Analysis-and-Growth-Opportunitieshttps://connect.rhabits.io/blogs/222292/Cell-Dissociation-Solution-Market-Analysis-Growth-Trends-Opportunities-and-Developmenthttps://www.nasseej.net/blogs/26106/Cell-Dissociation-Solution-Market-Size-Share-Top-Trends-Growth-andhttp://wwfanclub.com/blogs/179415/Cell-Dissociation-Solution-Market-Statistics-Segment-Trends-Size-Share-Typehttps://www.login.ps/blogs/25088/Cell-Dissociation-Solution-Market-to-Witness-an-Outstanding-Growth-byhttps://www.tamaiaz.com/blogs/32828/Cell-Dissociation-Solution-Market-Estimated-to-Flourish-at-by-2030https://heroes.app/blogs/225743/Cell-Dissociation-Solution-Market-Set-to-Witness-an-Uptick-duringhttps://www.exoltech.net/blogs/48740/Cell-Dissociation-Solution-Market-foreseen-to-grow-exponentially-over-2030https://gemawiraclub.com/blogs/7373/Cell-Dissociation-Solution-Market-Estimated-to-Experience-a-Hike-inhttps://social.studentb.eu/read-blog/72962https://kyourc.com/read-blog/63748https://yruz.one/blogs/18074/Cell-Dissociation-Solution-Market-Size-Share-Top-Trends-Growth-andhttps://moniispace.com/read-blog/21427http://eteria.net/read-blog/22390https://hissme.com/read-blog/52258https://blue.et/create-blog/#https://cryptofriender.com/read-blog/3136https://www.vkay.net/read-blog/3758https://socialblast.club/read-blog/3046https://legalledger.in/read-blog/12540https://talkin.co.ke/read-blog/5327https://baitk.com/read-blog/6101https://www.pickmemo.com/read-blog/130043https://stompster.com/read-blog/106510https://snapside.com/read-blog/699https://makenix.com/read-blog/20981https://ourclass.mn.co/posts/cell-dissociation-solution-market-revenue-growth-opportunities-and-dynamic-business-by-2030https://synkretic.mn.co/posts/cell-dissociation-solution-market-analytical-overview-and-sizevalue-and-volume-by-2030https://wecanchat.mn.co/posts/cell-dissociation-solution-market-growth-development-and-challenges-with-forecast-2030https://beranda.mn.co/posts/cell-dissociation-solution-market-key-futuristic-top-trends-and-competitive-landscape-by-2030https://janjaonline.mn.co/posts/cell-dissociation-solution-market-trends-and-dynamic-2030https://stemfemmes.mn.co/posts/cell-dissociation-solution-market-predicted-to-accelerate-the-growth-by-2023-2030https://markettrendsdotin.wordpress.com/2023/03/03/cell-dissociation-solution-market-global-forecasts-upto2023-2030/https://medium.com/@sandra_85356/cell-dissociation-solution-market-recent-trends-development-growth-and-forecast-2023-2030-29b6031825c2https://rentry.co/srwxmhttps://www.homify.co.uk/ideabooks/9286674/cell-dissociation-solution-market-detailed-analysis-and-forecast-2023-2030https://www.vingle.net/posts/5431951https://justpaste.it/37ogqhttps://pastelink.net/v7jnzgj4https://www.evernote.com/shard/s410/sh/37788eb2-85c0-5995-3cee-eee3c332b9e4/rYdOdclTzKvg5MP0un7lmISPj4nd-cDXaG5nexvwKkgJQrqT0TCjZCBY3Ahttps://onmogul.com/stories/cell-dissociation-solution-market-overview-and-regional-outlook-study-2023-2030https://www.findit.com/imhuropllouacvm/RightNow/cell-dissociation-solution-market-dynamic-business2/9d9230ab-5ed6-453a-99cc-f948c34c1f59https://markettrends.hashnode.dev/cell-dissociation-solution-market-to-witness-an-astonishing-growth-by-2030https://www.reddit.com/user/Material-World6244/comments/11gzvjm/cell_dissociation_solution_market_current_trends/https://gab.com/sandrak1/posts/109959418465430489https://uberant.com/article/1902666-cell-dissociation-solution-market-share-and-growth-factors-impact-analysis-2023-2030/https://www.diigo.com/item/note/9wuh3/m3dj?k=b6074282955eb51d792796e3cd7efcc4https://writeablog.net/cnmzpdk6kehttps://posteezy.com/cell-dissociation-solution-market-projected-witness-double-digit-cagr-during-2030http://prsync.com/markets-n-research/cell-dissociation-solution-market-to-witness-growth-acceleration-during--3702657/https://www.zupyak.com/p/3528065/t/cell-dissociation-solution-market-projected-to-be-resilient-during-2030https://www.xing.com/discover/detail-activities/6725664026.8d0e87?trackingTokens=disco.module.me-feed%3A584208bcb9c211ed80ed9a552be7ad33%3A0.6725664026.activities_activityhttps://blogfreely.net/sandrak1/cell-dissociation-solution-market-projected-to-witness-vigorous-expansion-byhttps://www.instapaper.com/read/1584858629https://www.pearltrees.com/sandrak1/item504304194https://www.bookmarkrush.com/submit-story/https://bookmarkfrog.com/submit-story/https://www.bookmarkrocket.com/submit-story/https://www.bookmarkmonk.com/submit-story/https://www.bookmarkmonk.com/story/cell-dissociation-solution-market-top-trends-present-history-future-and-forecast-2030/https://www.bookmarkrush.com/story/cell-dissociation-solution-market-poised-to-garner-maximum-revenues-during-2030/https://bookmarkfrog.com/story/cell-dissociation-solution-market-expansion-projected-to-gain-an-uptick-during-2030/https://www.bookmarkrocket.com/story/cell-dissociation-solution-market-newer-segments-of-application-2030/https://omiyou.com/read-blog/22132https://famenest.com/read-blog/26765https://network-1062788.mn.co/posts/33235761https://ubiz.chat/read-blog/39298https://vherso.com/read-blog/36958https://www.dr-ay.com/blogs/56741/Cell-Dissociation-Solution-Market-Current-Outlook-Of-Industry-Forecast-2023

Markets N Research1016 W Jackson Blvd Chicago, IL 60607 United StatesTel: +17736491529Email: sales@marketsnresearch.com

Markets N Research team is comprised of well skilled and equipped personnel ready to concur any upcoming challenges in the market sector for both individual people and organization around the world. We know time is money, and therefore we ensure we solve your problem within the shortest time possible to prevent delays or missing any opportunities. We use globally accepted techniques with a little innovation from our staff in solving all your market research related challenges.

This release was published on openPR.

Link:
Global Cell Dissociation Solution Market to Reach USD 872.8 Million by 2030; Increasing R&D Activites in Emerg - openPR

Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights – Yahoo Finance

Homology Medicines, Inc.

- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Yearwith First Participant Dosed and Others in Screening -

- Initial Clinical Data from Gene Therapy Trial for Hunter Syndrome Anticipatedin Second Half of 2023; Trial Recruiting in the U.S. and Canada -

- Anticipated Cash Runway Into Fourth Quarter 2024 Enables Execution Against Key Milestones -

BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent accomplishments.

We entered 2023 with strong momentum across our gene editing and gene therapy clinical trials for PKU and Hunter syndrome, and we anticipate initial data read-outs from both programs this year, said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. Dosing of the first patient in the pheEDIT trial for PKU marked a key milestone for Homology, and the forthcoming data will represent the first gene editing data in PKU patients. We believe the continued interest in the juMPStart trial for Hunter syndrome underscores the impact a one-time gene therapy with potential to address both the peripheral and CNS disease manifestations could have for patients and their loved ones.

Continued Dr. Seymour, We recently shared a series of data that support these programs, including preclinical work on the targeted immunosuppression regimen being utilized in both pheEDIT and juMPStart. We also unveiled details of our optimized MLD gene therapy candidate, demonstrating its ability to cross the blood-brain-barrier in the disease model with enzyme activity expected to lead to in vivo efficacy. The third arm of our platform, GTx-mAb, continues to advance as we move HMI-104 for PNH through IND-enabling studies. We are well-positioned to execute against key milestones with anticipated funding into the fourth quarter of 2024.

Story continues

Fourth Quarter 2022 and Recent Accomplishments

Dosed first participant in the Phase 1 pheEDIT clinical trial evaluating in vivo nuclease-free gene editing candidate HMI-103 in adults with phenylketonuria (PKU); additional participants are in screening. Homology continues to expect initial clinical data from the trial mid-year 2023.

Shared preclinical data that showed murine surrogate of HMI-103 was ten times more potent than non-integrating gene therapy vector HMI-102 in the murine model of PKU; HMI-103 is designed with a unique mechanism of action (MOA) to maximize PAH enzyme through both genome integration and episomal expression, and it has the potential to treat adults and pediatric patients.

Building on physician and patient interest, anticipate initial clinical data from the HMI-203 juMPStart gene therapy trial for Hunter syndrome in the second half of 2023.

Presented data that support the targeted immunosuppressive regimen in Homologys clinical trials. In non-human primates (NHPs), the combination of a T-cell inhibitor and steroid was most effective in reducing the immune response to AAVHSC and improving gene expression.

Presented preclinical data with HMI-204, Homologys optimized, in vivo gene therapy candidate for metachromatic leukodystrophy (MLD). A single I.V. dose in the murine model of MLD led to robust expression in the central nervous system (CNS), including sustained levels of enzyme activity reaching levels of normal human adults and predicted to lead to efficacy in vivo. Homology continues to seek a partner for the optimized product candidate, which is ready to enter IND-enabling studies.

Progressed HMI-104, a C5 monoclonal antibody (mAb) development candidate for paroxysmal nocturnal hemoglobinuria (PNH), through IND-enabling studies. HMI-104 is the first candidate that utilizes the Companys GTx-mAb platform and is focused on using the liver to express a C5 mAb with a one-time dose. Homology believes its GTx-mAb platform has the potential to address larger market indications.

Announced today thepromotion of Julie Jordan, M.D., to Chief Medical Officer.

Fourth Quarter 2022 and Full Year Financial Results

Net loss for the quarter ended December 31, 2022 was $(34.3) million or $(0.60) per share, compared to a net loss of $(33.6) million or $(0.59) per share for the same period in 2021. Net loss for the year ended December 31, 2022 was $(5.0) million or $(0.09) per share, compared to a net loss of $(95.8) million or $(1.73) per share for the same period in 2021. The decrease in net loss was primarily due to a gain of $131.2 million realized in connection with the Companys sale of its manufacturing business to Oxford Biomedica in order to establish Oxford Biomedica Solutions (OXB Solutions), an AAV Innovation and Manufacturing Business, in the first quarter of 2022, partially offset by lower collaboration revenues in 2022.

Collaboration revenues for the three and twelve months ended December 31, 2022 were $0.8 million and $3.2 million, respectively, as compared to $0.8 million and $34.0 million for the comparable periods in 2021. Collaboration revenues in 2022 consisted of revenue recognized under the Companys stock purchase agreement with Pfizer compared with collaboration revenues in 2021, which were primarily the result of concluding the Companys collaboration with Novartis.

Total operating expenses for the three and twelve months ended December 31, 2022 were $35.3 million and $136.5 million, respectively, as compared to $34.4 million and $129.9 million for the comparable periods in 2021, and consisted of research and development expenses and general and administrative expenses.

Research and development expenses for the three and twelve months ended December 31, 2022 were $27.2 million and $98.4 million, respectively, as compared to $23.6 million and $93.1 million for the comparable periods in 2021. Research and development expenses increased by $5.3 million in 2022 primarily due to increases in direct costs of $9.3 million related to pheEDIT and $3.9 million related to juMPStart, as we incurred costs to initiate sites and recruit patients. Additionally, there was a $5.8 million increase in direct research expenses related to our other development-stage programs, primarily due to higher spending on HMI-104. Partially offsetting these increases was a $15.6 million decrease in employee-related costs as a result of transferring employees to OXB Solutions in order to leverage the Companys in-house manufacturing capabilities while establishing a 20% ownership stake and preferred customer status in the new business.

General and administrative expenses for the three and twelve months ended December 31, 2022 were $8.1 million and $38.1 million, respectively, as compared to $10.8 million and $36.8 million for the comparable periods in 2021. General and administrative expenses increased in 2022 due primarily to professional fees associated with the establishment of OXB Solutions.

As of December 31, 2022, Homology had approximately $175.0 million in cash, cash equivalents and short-term investments. Based on current projections, Homology expects current cash resources to fund operations into the fourth quarter of 2024.

Upcoming Events

About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Companys clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homologys proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines in vivo through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homologys internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit http://www.homologymedicines.com.

Forward-Looking Statements This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: our plans to engage in future collaborations and strategic partnerships; our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our plans to progress our pipeline of genetic medicine candidates and the anticipated timing for these milestones; our position as a leader in the development of genetic medicines; the sufficiency of our cash and cash equivalents to fund our operations; and our participation in upcoming presentations and conferences. The words believe, may, will, estimate, potential, continue, anticipate, intend, expect, could, would, project, plan, target, and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies and clinical trials; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

- Financial Tables Follow -

HOMOLOGY MEDICINES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

December31,

2022

2021

Cash, cash equivalents and short-term investments

$

175,026

$

155,873

Assets held for sale

28,907

Equity method investment

25,814

Property and equipment, net

1,078

2,252

Right-of-use assets

20,563

15,607

Other assets

5,989

9,082

Total assets

$

228,470

Read the original post:
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights - Yahoo Finance

Development of an immune-related gene prognostic risk model and … – BMC Gastroenterology

Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, Lim YC, Kibria KMK, Mohiuddin AKM, Ming LC, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers. 2022;14(7):1732.

Article PubMed PubMed Central Google Scholar

Jia S-N, Han Y-B, Yang R, Yang Z-C. Chemokines in colon cancer progression. Semin Cancer Biol. 2022;86(Pt 3):4007.

Article CAS PubMed Google Scholar

Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for colorectal cancer screening. Gastroenterology. 2020;158(2):41832.

Article CAS PubMed Google Scholar

Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479516.

Article CAS PubMed Google Scholar

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):32959.

Article PubMed Google Scholar

Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. PD-1/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:3128.

Article CAS PubMed Google Scholar

Kather JN, Halama N, Jaeger D. Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Semin Cancer Biol. 2018;52(Pt 2):18997.

Article CAS PubMed Google Scholar

Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):111320.

Article PubMed PubMed Central Google Scholar

Shankar RD, Bhattacharya S, Jujjavarapu C, Andorf S, Wiser JA, Butte AJ. RImmPort: an R/bioconductor package that enables ready-for-analysis immunology research data. Bioinformatics. 2017;33(7):11013.

Article CAS PubMed Google Scholar

Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, Hu Z, Zalocusky KA, Shankar RD, Shen-Orr SS, et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018;5: 180015.

Article CAS PubMed PubMed Central Google Scholar

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e10810.

Article CAS PubMed PubMed Central Google Scholar

Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, Shin H, Wong SS, Ma J, Lei Y, et al. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol. 2011;12(8):R83.

Article CAS PubMed PubMed Central Google Scholar

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498504.

Article CAS PubMed PubMed Central Google Scholar

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):20949.

Article PubMed Google Scholar

Wang Y, Zhang X, Dai X, He D. Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma. Expert Rev Anticancer Ther. 2021;21(10):116170.

Article CAS PubMed Google Scholar

He W, Wang B, He J, Zhao Y, Zhao W. SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma. Expert Rev Mol Diagn. 2022;22(2):22331.

Article CAS PubMed Google Scholar

Duan L, Yang W, Wang X, Zhou W, Zhang Y, Liu J, Zhang H, Zhao Q, Hong L, Fan D. Advances in prognostic markers for colorectal cancer. Expert Rev Mol Diagn. 2019;19(4):31324.

Article CAS PubMed Google Scholar

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):54150.

Article CAS PubMed PubMed Central Google Scholar

Plundrich D, Chikhladze S, Fichtner-Feigl S, Feuerstein R, Briquez PS. Molecular mechanisms of tumor immunomodulation in the microenvironment of colorectal cancer. Int J Mol Sci. 2022;23(5):2782.

Article CAS PubMed PubMed Central Google Scholar

Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):55972.

Article CAS PubMed PubMed Central Google Scholar

Frigerio S, Lartey DA, DHaens GR, Grootjans J. The role of the immune system in IBD-associated colorectal cancer: from pro to anti-tumorigenic mechanisms. Int J Mol Sci. 2021;22(23):12739.

Article CAS PubMed PubMed Central Google Scholar

Jin K, Ren C, Liu Y, Lan H, Wang Z. An update on colorectal cancer microenvironment, epigenetic and immunotherapy. Int Immunopharmacol. 2020;89(Pt A): 107041.

Article CAS PubMed Google Scholar

Umansky V, Blattner C, Fleming V, Hu X, Gebhardt C, Altevogt P, Utikal J. Myeloid-derived suppressor cells and tumor escape from immune surveillance. Semin Immunopathol. 2017;39(3):295305.

Article CAS PubMed Google Scholar

Garrido F, Perea F, Bernal M, Sanchez-Palencia A, Aptsiauri N, Ruiz-Cabello F. The escape of cancer from T cell-mediated immune surveillance: HLA class I loss and tumor tissue architecture. Vaccines (Basel). 2017;5(1):7.

Article PubMed Google Scholar

Dumauthioz N, Labiano S, Romero P. Tumor resident memory T cells: new players in immune surveillance and therapy. Front Immunol. 2018;9:2076.

Article PubMed PubMed Central Google Scholar

Pags F, Mlecnik B, Marliot F, Bindea G, Ou F-S, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):212839.

Article PubMed Google Scholar

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698711.

Article CAS PubMed Google Scholar

Tang YQ, Chen TF, Zhang Y, Zhao XC, Zhang YZ, Wang GQ, Huang ML, Cai SL, Zhao J, Wei B, et al. The tumor immune microenvironment transcriptomic subtypes of colorectal cancer for prognosis and development of precise immunotherapy. Gastroenterol Rep (Oxf). 2020;8(5):3819.

Article PubMed Google Scholar

Qie D, Zhang Y, Gong X, He Y, Qiao L, Lu G, Li Y. SLC10A2 deficiency-induced congenital chronic bile acid diarrhea and stunting. Mol Genet Genomic Med. 2021;9(8): e1740.

Article CAS PubMed PubMed Central Google Scholar

Raufman JP, Dawson PA, Rao A, Drachenberg CB, Heath J, Shang AC, Hu S, Zhan M, Polli JE, Cheng K. Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. Carcinogenesis. 2015;36(10):1193200.

Article CAS PubMed PubMed Central Google Scholar

Mukherjee A, Chiang CY, Daifotis HA, Nieman KM, Fahrmann JF, Lastra RR, Romero IL, Fiehn O, Lengyel E. Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance. Cancer Res. 2020;80(8):174861.

Article CAS PubMed Google Scholar

Ji L, Qian W, Gui L, Ji Z, Yin P, Lin GN, Wang Y, Ma B, Gao WQ. Blockade of beta-catenin-induced CCL28 suppresses gastric cancer progression via inhibition of Treg cell infiltration. Cancer Res. 2020;80(10):200416.

Article CAS PubMed Google Scholar

Zhu C, Sun Z, Li C, Guo R, Li L, Jin L, Wan R, Li S. Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2. Cell Signal. 2014;26(5):112534.

Article CAS PubMed Google Scholar

Teng Y, Guo B, Mu X, Liu S. KIF26B promotes cell proliferation and migration through the FGF2/ERK signaling pathway in breast cancer. Biomed Pharmacother. 2018;108:76673.

Article CAS PubMed Google Scholar

Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41-52.

Article PubMed PubMed Central Google Scholar

Teng G, Papavasiliou FN. Immunoglobulin somatic hypermutation. Annu Rev Genet. 2007;41:10720.

Article CAS PubMed Google Scholar

Pan KF, Lee WJ, Chou CC, Yang YC, Chang YC, Chien MH, Hsiao M, Hua KT. Direct interaction of beta-catenin with nuclear ESM1 supports stemness of metastatic prostate cancer. EMBO J. 2021;40(4): e105450.

Article CAS PubMed Google Scholar

Giulianelli R, Nardoni S, Bruzzese D, Falavolti C, Mirabile G, Bellangino M, Tema G, Gentile BC, Albanesi L, Buscarini M, et al. Urotensin II receptor expression in prostate cancer patients: a new possible marker. Prostate. 2019;79(3):28894.

Article CAS PubMed Google Scholar

Hirayasu Y, Oya M, Okuyama T, Kiumi F, Ueda Y. Vasoactive intestinal peptide and its relationship to tumor stage in colorectal carcinoma: an immunohistochemical study. J Gastroenterol. 2002;37:33644.

Article PubMed Google Scholar

Fernandez-Martinez AB, Bajo AM, Sanchez-Chapado M, Prieto JC, Carmena MJ. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. Prostate. 2009;69(7):77486.

Article CAS PubMed Google Scholar

Hara M, Takeba Y, Iiri T, Ohta Y, Ootaki M, Watanabe M, Watanabe D, Koizumi S, Otsubo T, Matsumoto N. Vasoactive intestinal peptide increases apoptosis of hepatocellular carcinoma by inhibiting the cAMP/Bcl-xL pathway. Cancer Sci. 2019;110(1):23544.

Article CAS PubMed Google Scholar

Wen S, He L, Zhong Z, Mi H, Liu F. Prognostic model of colorectal cancer constructed by eight immune-related genes. Front Mol Biosci. 2020;7: 604252.

Article CAS PubMed PubMed Central Google Scholar

Shani O, Vorobyov T, Monteran L, Lavie D, Cohen N, Raz Y, Tsarfaty G, Avivi C, Barshack I, Erez N. Fibroblast-derived IL33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type 2 immunity. Cancer Res. 2020;80(23):531729.

Article CAS PubMed PubMed Central Google Scholar

Wu R, Li K, Yuan M, Luo KQ. Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells. Oncogene. 2021;40(12):216581.

Article CAS PubMed Google Scholar

Parsi S, Soltani BM, Hosseini E, Tousi SE, Mowla SJ. Experimental verification of a predicted intronic microRNA in human NGFR gene with a potential pro-apoptotic function. PLoS ONE. 2012;7(4): e35561.

Article CAS PubMed PubMed Central Google Scholar

Sobrero AF, Puccini A, Shi Q, Grothey A, Andre T, Shields AF, Souglakos I, Yoshino T, Iveson T, Ceppi M, et al. A new prognostic and predictive tool for shared decision making in stage III colon cancer. Eur J Cancer. 2020;138:1828.

Article CAS PubMed Google Scholar

Qaderi SM, Dickman PW, de Wilt JHW, Verhoeven RHA. Conditional survival and cure of patients with colon or rectal cancer: a population-based study. J Natl Compr Canc Netw. 2020;18(9):12307.

Article PubMed Google Scholar

Li Q, Cai G, Li D, Wang Y, Zhuo C, Cai S. Better long-term survival in young patients with non-metastatic colorectal cancer after surgery, an analysis of 69,835 patients in SEER database. PLoS ONE. 2014;9(4): e93756.

Article PubMed PubMed Central Google Scholar

Weinberg BA, Marshall JL. Colon cancer in young adults: trends and their implications. Curr Oncol Rep. 2019;21(1):3.

Article PubMed Google Scholar

Vinuesa AG, Sancho R, Garcia-Limones C, Behrens A, ten Dijke P, Calzado MA, Munoz E. Vanilloid receptor-1 regulates neurogenic inflammation in colon and protects mice from colon cancer. Cancer Res. 2012;72(7):170516.

Article CAS PubMed Google Scholar

Read this article:
Development of an immune-related gene prognostic risk model and ... - BMC Gastroenterology

Growth changes of tomato seedlings responding to sodium salt of … – Nature.com

Gebrehiwot, A. A. et al. Using ABM to study the potential of land use change for mitigation of food deserts. Sustainability 14(15), 9715. https://doi.org/10.3390/su14159715 (2022).

Article Google Scholar

Verma, B., Pramanik, P., & Bhaduri, D. Organic fertilizers for sustainable soil and environmental management. in Nutrient Dynamics for Sustainable Crop Production (Meena, R.S. Ed.). 289313 (Springer, 2020).

Droste, N. et al. Soil carbon insures arable crop production against increasing adverse weather due to climate change. Environ. Res. Lett. https://doi.org/10.1088/1748-9326/abc5e3 (2020).

Article Google Scholar

Daba, N. et al. Long-term fertilization and lime-induced soil pH changes affect nitrogen use efficiency and grain yields in acidic soil under wheat-maize rotation. Agronomy 11, 2069. https://doi.org/10.3390/agronomy11102069 (2021).

Article CAS Google Scholar

Yan, L. et al. Spatiotemporal distribution of chemical fertilizer application and manure application potential in China. Environ. Eng. Sci. 36, 13371348. https://doi.org/10.1089/ees.2018.0486 (2019).

Article CAS Google Scholar

Gang-Hua, L. I. High quality and high efficiency fertilization of rice. J. Integr. Agric. 20, 14351437. https://doi.org/10.1016/S2095-3119(21)63683-3 (2021).

Article Google Scholar

Warsame, A. A., Mohamed, J. & Mohamed, A. A. The relationship between environmental degradation, agricultural crops, and livestock production in somalia. Environ. Sci. Pollut. Res. Int. 30(3), 78257835. https://doi.org/10.1007/s11356-022-22595-8 (2023).

Article PubMed Google Scholar

Wu, J. et al. More land, less pollution? How land transfer affects fertilizer application. Int. J. Environ. Res. Public Health 18, 11268. https://doi.org/10.3390/ijerph182111268 (2021).

Article PubMed PubMed Central Google Scholar

Ye, L. et al. Bio-organic fertilizer with reduced rates of chemical fertilization improves soil fertility and enhances tomato yield and quality. Sci. Rep.-UK 10, 1. https://doi.org/10.1038/s41598-019-56954-2 (2020).

Article CAS Google Scholar

Li, X. Decision-making behavior of fertilizer application of grain growers in Heilongjiang Province from the perspective of risk preference and risk perception. Math. Probl. Eng. https://doi.org/10.1155/2021/6667558 (2021).

Article Google Scholar

Stuart, A. M. et al. Yield gaps in rice-based farming systems: Insights from local studies and prospects for future analysis. Field Crops Res. 194, 4356. https://doi.org/10.1016/j.fcr.2016.04.039 (2016).

Article Google Scholar

Yueyue, T. et al. Effects of plant growth regulators on flower abscission and growth of tea plant Camellia sinensis (L.) O. Kuntze. J. Plant Growth Regul. 41(3), 11611173. https://doi.org/10.1007/s00344-021-10365-8 (2022).

Article CAS Google Scholar

Liu, C. et al. Novel plant growth regulator guvermectin from plant growth-promoting rhizobacteria boosts biomass and grain yield in rice. J. Agricult. Food Chem. 70(51), 1622916240. https://doi.org/10.1021/acs.jafc.2c07072 (2022).

Article CAS Google Scholar

Widyastuti, T. The paclobutrazol application and pinching technique on lisianthus plants. Earth Environ. Sci. 752, 1. https://doi.org/10.1088/1755-1315/752/1/012055 (2021).

Article Google Scholar

Hajihashemi, S. Physiological, biochemical, antioxidant and growth characterizations of gibberellin and paclobutrazol-treated sweet leaf herb. J. Plant Biochem. Biotechnol. 27(2), 237240. https://doi.org/10.1007/s13562-017-0428-4 (2018).

Article MathSciNet CAS Google Scholar

Khan, N., Bano, A. & Babar, M. D. A. Impacts of plant growth promoters and plant growth regulators on rainfed agriculture. PLoS ONE 15(4), 1. https://doi.org/10.1371/journal.pone.0231426 (2020).

Article CAS Google Scholar

Bhalla, K., Singh, S. B. & Agarwal, R. Quantitative determination of gibberellins by high performance liquid chromatography from various gibberellins producing fusarium strains. Environ. Monit. Assess. 167(14), 515520. https://doi.org/10.1007/s10661-009-1068-5 (2010).

Article CAS PubMed Google Scholar

Dos Santos, J. A. et al. Morphophysiological changes by mepiquat chloride application in eucalyptus clones. Trees 35(1), 189198. https://doi.org/10.1007/s00468-020-02021-7 (2021).

Article CAS Google Scholar

Arampatzis, D. A., Karkanis, A. C. & Tsiropoulos, N. G. Impact of plant density and mepiquat chloride on growth, yield, and silymarin content of Silybum marianum grown under Mediterranean semi-arid conditions. Agronomy 9(11), 669. https://doi.org/10.3390/agronomy9110669 (2019).

Article CAS Google Scholar

Anastassiadou, M. et al. Modification of the temporary maximum residue level for mepiquat in oyster mushrooms. EFSA J. 17, 7. https://doi.org/10.2903/j.efsa.2019.5744 (2019).

Article Google Scholar

Dalimunthe, R. H., Setiado, H., Lubis, K. & Damanik, R. I. Effect of paclobutrazol in micro tuberization of potato cultivar Granola Kembang and Repita (IOP Conference Series) (Earth and Environmental Science, 2021). https://doi.org/10.1088/1755-1315/782/4/042058.

Book Google Scholar

Bao, W. et al. A single gene transfer of gibberellin biosynthesis gene cluster increases gibberellin production in a Fusarium fujikuroi strain with gibberellin low producibility. Plant Pathol. 69(5), 901910. https://doi.org/10.1111/ppa.13176 (2020).

Article CAS Google Scholar

Le, V. N. et al. The potential health risks and environmental pollution associated with the application of plant growth regulators in vegetable production in several suburban areas of Hanoi, Vietnam. Biol. Futura 71(3), 323331. https://doi.org/10.1007/s42977-020-00041-5 (2020).

Article CAS Google Scholar

Ricci, M., Tilbury, L., Daridon, B. & Sukalac, K. General principles to justify plant biostimulant claims. Front. Plant Sci. 10, 494. https://doi.org/10.3389/fpls.2019.00494 (2019).

Article PubMed PubMed Central Google Scholar

Essawy, H. A. et al. Potassium fulvate-functionalized graft copolymer of polyacrylic acid from cellulose as a promising selective chelating sorben. RSC Adv. 7, 2017820185. https://doi.org/10.1039/C7RA02646C (2017).

Article ADS CAS Google Scholar

Canellas, L. P. et al. Humic and fulvic acids as biostimulants in horticultureA review. Sci. Hortic. 196, 1527. https://doi.org/10.1016/j.scienta.2015.09.013 (2013).

Article CAS Google Scholar

Ghazy, M. et al. Potassium fulvate as co-interpenetrating agent during graft polymerization of acrylic acid from cellulose. Int. J. Biol. Macromol. https://doi.org/10.1016/j.ijbiomac.2016.06.088 (2016).

Article PubMed Google Scholar

Elrys, A. S. et al. Integrative application of licorice root extract or lipoic acid with fulvic acid improves wheat production and defenses under salt stress conditions. Ecotoxicol. Environ. Saf. 190, 110144. https://doi.org/10.1016/j.ecoenv.2019.110144 (2020).

Article CAS PubMed Google Scholar

Cayn Salinas, D. G. et al. Application of naphthalene acetic acid and gibberellic acid favours fruit induction and development in oil palm hybrid (Elaeis oleifera x Elaeis guineensis). Exp. Agric. https://doi.org/10.1017/S001447972200031X (2022).

Article Google Scholar

Ahmad, A. S., Abramov, A. G., Shalamova, A. A. & Antar, M. B. Effect of humic acid and naphthalene acetic acid on vegetative growth and fruit quality of tomato plants lycopersicon esculentum. Vestnik Rossijskogo Univ. Druby Narodov 15(1), 3039. https://doi.org/10.22363/2312-797X-2020-15-1-30-39 (2020).

Article Google Scholar

Xing, X. et al. Improved drought tolerance by -naphthaleneacetic acid-induced ROS accumulation in two soybean cultivars. J. Integr. Agric. https://doi.org/10.1016/S2095-3119(15)61273-4 (2016).

Article Google Scholar

Yang, F. et al. Plant growth regulation enhanced potassium uptake and use efficiency in cotton. Field Crops Res. 163, 109118. https://doi.org/10.1016/j.fcr.2014.03.016 (2014).

Article Google Scholar

Zhang, H. J., Zhang, H. Y. & Yu, J. H. Effects of -naphthalene acetic acid sodium on yield and endogenous hormones of greenhouse grown pepper in desert area. J. Desert Res. 33, 13901399 (2013).

Google Scholar

Ali, M., Mujib, A., Zafar, N. & Tonk, D. Somatic embryogenesis, biochemical alterations and synthetic seed development in two varieties of coriander (Coriandrum sativum L.). Adv. Hortic. Sci. 32(2), 239248. https://doi.org/10.13128/ahs-22287 (2018).

Article Google Scholar

Hesami, M., Daneshvar, M. H. & Yoosefzadeh-Najafabadi, M. An efficient in vitro shoot regeneration through direct organogenesis from seedling-derived petiole and leaf segments and acclimatization of Ficus religiosa. J. For. Res. 30(3), 807815. https://doi.org/10.1007/s11676-018-0647-0 (2019).

Article CAS Google Scholar

Ren, M. et al. Assessing the genetic improvement in inbred late rice against chilling stress: Consequences for spikelet fertility, pollen viability and anther characteristics. Agronomy 12, 1894. https://doi.org/10.3390/agronomy12081894 (2022).

Article Google Scholar

Rahimi, A., Mohammadi, M. M., Siavash Moghaddam, S., Heydarzadeh, S. & Gitari, H. Effects of stress modifier biostimulants on vegetative growth, nutrients, and antioxidants contents of garden thyme (Thymus vulgaris L.) under water deficit conditions. J. Plant Growth Regul. 41(5), 20592072. https://doi.org/10.1007/s00344-022-10604-6 (2022).

Article CAS Google Scholar

Noh, E., Fallen, B., Payero, J. & Narayanan, S. Parsimonious root systems and better root distribution can improve biomass production and yield of soybean. PLoS ONE https://doi.org/10.1371/journal.pone.0270109 (2022).

Article PubMed PubMed Central Google Scholar

Halpern, M. et al. Chapter two: The use of biostimulants for enhancing nutrient uptake. Adv. Agron. 130, 141174. https://doi.org/10.1016/bs.agron.2014.10.001 (2015).

Article Google Scholar

Liu, L. et al. Direct evidence of drought stress memory in mulberry from a physiological perspective: Antioxidative, osmotic and phytohormonal regulations. Plant Physiol. Biochem. (PPB) 186, 7687. https://doi.org/10.1016/j.plaphy.2022.07.001 (2022).

Article CAS PubMed Google Scholar

Liang, J. et al. Dualistic effects of bisphenol A on growth, photosynthetic and oxidative stress of duckweed (Lemna minor). Environ. Sci. Pollut. Res. Int. 29(58), 8771787729. https://doi.org/10.1007/s11356-022-21785-8 (2022).

Article CAS PubMed Google Scholar

Lixiao, N. et al. Enhancement in seed priming-induced starch degradation of rice seed under chilling stress via GA-mediated -amylase expression. Rice https://doi.org/10.1186/s12284-022-00567-3 (2022).

Article Google Scholar

Gu, K. et al. The physiological response of different tobacco varieties to chilling stress during the vigorous growing period. Sci. Rep. 11(1), 22136. https://doi.org/10.1038/s41598-021-01703-7 (2021).

Article ADS CAS PubMed PubMed Central Google Scholar

Li, F. et al. Application of enzymatic hydrolysate of Ulva clathrata as biostimulant improved physiological and metabolic adaptation to salt-alkaline stress in wheat. J. Appl. Phycol. 34(3), 17791789. https://doi.org/10.1007/s10811-022-02684-4 (2022).

Article CAS Google Scholar

Wang, W. et al. Animal-derived plant biostimulant alleviates drought stress by regulating photosynthesis, osmotic adjustment, and antioxidant systems in tomato plants. Sci. Hortic. https://doi.org/10.1016/j.scienta.2022.111365 (2022).

Article Google Scholar

Chi, Y. et al. Utilization of Durvillaea antarctica (Chamisso) Hariot extract as a biostimulant to enhance the growth of cucumber (Cucumis sativus L.) seedlings. J. Plant Growth Regul. 41(8), 32083217. https://doi.org/10.1007/s00344-021-10506-z (2022).

Article CAS Google Scholar

Duan, R., Ma, Y., & Yang, L. Effects of shading on photosynthetic pigments and photosynthetic parameters of Lespedeza buergeri seedlings. in IOP Conference Series. Materials Science and Engineering Vol. 452(2). https://doi.org/10.1088/1757-899X/452/2/022158 (2018).

Li, J. et al. Seasonal changes of leaf chlorophyll content as a proxy of photosynthetic capacity in winter wheat and paddy rice. Ecol. Indic. https://doi.org/10.1016/j.ecolind.2022.109018 (2022).

Article Google Scholar

Mozhgan, A., Kazemeini, S. A., Mozhgan, S. & Ali, D. Simultaneous application of rhizobium strain and melatonin improves the photosynthetic capacity and induces antioxidant defense system in common bean (Phaseolus vulgaris L.) under salinity stress. J. Plant Growth Regul. 41(3), 13671381. https://doi.org/10.1007/s00344-021-10386-3 (2022).

Article CAS Google Scholar

Sun, M. et al. Effects of mesotrione on the control efficiency and chlorophyll fluorescence parameters of Chenopodium album under simulated rainfall conditionss. PLoS ONE https://doi.org/10.1371/journal.pone.0267649 (2022).

Article PubMed PubMed Central Google Scholar

Singh, H., Kumar, D. & Soni, V. Performance of chlorophyll a fluorescence parameters in lemna minor under heavy metal stress induced by various concentration of copper. Sci. Rep. 12(1), 10620. https://doi.org/10.1038/s41598-022-14985-2 (2022).

Article ADS CAS PubMed PubMed Central Google Scholar

Read more:
Growth changes of tomato seedlings responding to sodium salt of ... - Nature.com

Andrew Painter has UCL sprain, will be shut down for four weeks – The Morning Call

CLEARWATER, Fla. The long-awaited Phillies medical update on Andrew Painter arrived Friday, and its not the best news. It also isnt the worst.

Painter has a sprain in his ulnar collateral ligament, and the 19-year-old prospect will rest for four weeks to see if he can avoid Tommy John surgery.

Painter had an MRI-arthrogram March 3 which revealed what manager Rob Thomson took pains to call a mild sprain. That diagnosis by team doctors was confirmed in a consultation with Dr. Neal ElAttrache, the surgeon who performed Bryce Harpers Tommy John procedure in November.

Obviously, its a bummer, Painter told media at BayCare Ballpark. You want to stay healthy, but at the end of the day, weve got to do whats right for the long-term. Its a long season. Weve got to take the precautions now and make sure Im healthy for the middle and the end of the year.

The sprain means a degree of stretching and/or minor tear in the ligament. Severe tears require reconstruction, which is the Tommy John procedure.

Like Harper, who tore the UCL in his right elbow last year, the Phillies will try to rest Painter to see if it heals, then re-evaluate him as he begins a light throwing program. The four weeks are from the date of his last outing, March 1. The treatment plan does not include platelet-rich plasma injections, which Harper had last year in his unsuccessful bid to avoid going under the knife.

Painter reported a tender feeling one day after his outing against Minnesota. He said nothing felt amiss during that start. Finalizing a diagnosis has taken a week, a process of patience for Painter.

Its been interesting, he said. Theres been a lot of concerns and weve been waiting a little bit. But Ive been fine. I havent been too worried about it. With our medical staff and everyones that had a say in this, theyre very experienced and they know what theyre doing.

All things considered, Thomson feels OK with the diagnosis. UCL strains dont automatically lead to Tommy John one example is Aaron Nola, who was shut down in August 2016 with a low-grade UCL strain. He avoided surgery and has become an All-Star workhorse since.

Nola sought out Painter when he heard about the younger pitchers issues last week and shared his experience, which included eight weeks off (it was the end of the season) and a PRP injection.

Hes 19. Nineteen-year-old bodies heal a lot quicker than 29-year-old bodies nowadays, Nola said. I pray for him, I hope everything works out, hope he doesnt have to get surgery, hope he heals really quick and its nothing super big.

This is a common thing, Painter said. Other people have experienced this. They know what were doing is right.

Painter is the Phillies top prospect and ranked by MLB.com as the sixth best in baseball. He went 6-2 with a 1.48 ERA last year in Single A and Double A, striking out 155 batters and walking 25 in 103.2 innings. He had been competing for the fifth spot in the rotation.

Given his age and potential, its possible this could help the Phillies later in the season. Painter will be on an innings limit so early in his career, and innings he misses in April might be available come September and (the Phillies hope) October.

For the rest of spring, Painter will be positioning himself for when hes able to throw again.

Its just staying on top of the recovery process and make sure I do everything in my power to make sure this recovery goes as well as planned, he said. And then just try to get on the mound whenever the time is right.

Follow this link:
Andrew Painter has UCL sprain, will be shut down for four weeks - The Morning Call

Osteoarthritis: Symptoms, Causes, and Treatments – Verywell Health

Osteoarthritis (OA) is the most prevalent type of arthritis. It occurs when the smooth, slippery cartilage that coats the endings of bones begins to deteriorate at a joint (where two bones meet). This wear and tear can increase friction, bone spurring, pain, and stiffness.

Though OA can develop at any joint, it is most common in the hands, spine, knees, hips, and feet.

This article will outline the most common causes, symptoms, and treatments for osteoarthritis.

Srdjan Radevic / EyeEm

When two bones meet, a joint forms. A smooth, slippery coatingcalled cartilagecoats the endings of bones and helps one glide against the other.

Several hallmark symptoms are typically seen with osteoarthritis. Some of the most common are:

In addition, several specific signs may present depending on which joint is affected. This includes:

Many people hear that a lifetime of physical activity or exercise can develop osteoarthritis in their bones and joints. However, a recent review dispelled this myth and found moderate physical activity does not cause OA to develop. Instead, it identified several other potential causes, including:

Many OA risk factors may potentially elevate your likelihood of developing osteoarthritis. These include:

The research establishing these risk factors is still in progress. Speak to a healthcare provider about your specific situation and any personal risk factors that may need modifying.

Preventing osteoarthritis from progressing or becoming symptomatic may be possible if you address some of the conditions risk factors. Some strategies that may benefit you include:

There are significant differences between osteoarthritis and rheumatoid arthritis. For example:

There are significant differences between osteoarthritis and rheumatoid arthritis.

As previously mentioned, osteoarthritis occurs after wear and tear cause a bones cartilage to deteriorate at a joint. This increases friction, excessive bony buildup, and pain or soreness. OA commonly affects weight-bearing joints (like the hips or knees) and frequently occurs on only one side of the body.

Rheumatoid arthritis (RA), on the other hand, is an autoimmune disease that causes your bodys immune system to attack its joint tissue. This tissue damage frequently leads to pain, swelling, and inflammation. RA most commonly impacts smaller joints, like those in the hands or feet, and is usually seen simultaneously on both sides of the body.

To accurately diagnose osteoarthritis, a healthcare provider usually performs a comprehensive evaluation. During this process, they will examine the affected joint(s) and take a personal history of your symptoms.

They may also obtain an X-ray to provide a clear image of the joint in question. This test can show damage to your bone, bone spurring, and any loss of space within the affected joint.

Finally, they can order magnetic resonance imaging (MRI) if they suspect concurrent damage to the muscles, ligaments, tendons, or other soft tissue structures.

Depending on the severity of your arthritis symptoms, they may suggest several different treatment strategies. The most common are outlined below.

Pain relievers or non-steroidal anti-inflammatory drug (NSAID) medications are frequently recommended to help treat OA pain and inflammation. Pain-relieving creams, rubs, or sprays may also help. Occasionally, a stronger corticosteroid may need to be taken orally or injected into the joint to alleviate a severe OA aggravation.

One of the biggest lifestyle changes you can make to impact your OA symptoms is maintaining a healthy body weight. Losing excess weight can:

Staying active with an exercise program focusing on strength, flexibility, and cardiovascular fitness is another cornerstone of OA self-care. A healthcare provider can guide safe ways to begin a new fitness regimen. They may also refer you to physical therapy for more structured guidance on appropriate osteoarthritis exercise techniques.

In severe cases of OA, surgery may be necessary. This is especially true if more conservative treatments fail to relieve your symptoms.

Depending on the affected area, this may involve a joint replacement (arthroplasty) or a joint fusion (arthrodesis) procedure. Occasionally, osteotomy surgery may also be recommended. This operation involves removing a piece of bone to alleviate pressure on the arthritic portion of the joint.

In some situations, a brace can reduce some of your osteoarthritis pain.

Most commonly utilized for knee arthritis, braces can:

Similar devices may also be recommended for osteoarthritis in your fingers, wrists, ankles, or elbows. Though bracing an arthritic area will not prevent OA from advancing, it may provide short-term enhancements to your day-to-day function and diminish some of your pain.

Several other treatments may help you manage your osteoarthritis pain.

Because platelets play a role in regenerating tissue and controlling inflammation, some have recommended platelet-rich plasma (PRP) injections for OA. Unfortunately, the research on this intervention is still mixed. Currently, there is low-level evidence showing that PRP injections may provide short- and medium-term pain relief for osteoarthritis.

Stem cell therapy has also been proposed as a potential management strategy. Stem cells are thought to help regenerate cartilage and reduce inflammation levels. Unfortunately, the evidence supporting this treatment is also still mixed. Several low-quality studies found reduced evidence of osteoarthritis and diminished pain levels after receiving this treatment. More research in this area is still necessary, however.

There is currently no evidence-based treatment that reverses osteoarthritis. That said, the presence of OA on an X-ray does not necessarily mean that you will have symptoms. It is possible to have osteoarthritis and minimal to no pain.

By staying active, maintaining a healthy body weight, taking medications as prescribed, and wearing braces if recommended, you may be able to keep pain levels low while continuing with the activities you love.

Osteoarthritis usually progresses slowly and gets worse as time goes on. As the cartilage in a joint thins, friction increases with movement and triggers bone spurs. This bone adds to the irregularity of the joint surface and begins to cause inflammation, swelling, and pain.

Though these symptoms may be mild and infrequent at first, over time, the pain from severe osteoarthritis may become more intense and constant. Other factors like heavy loading of the affected joint and excessive body weight can also accelerate this process.

To remain active and maintain a healthy body weight in spite of osteoarthritis, try following these steps:

OA can cause severe pain and significantly limit overall mobility if inadequately treated. This shift to a more sedentary lifestyle may also lead to the development of other health conditions like obesity, metabolic syndrome, and diabetes.

Fortunately, many cases of osteoarthritis are effectively managed with the conservative treatments listed above. Working closely with a healthcare provider can help avoid these potential side effects and ensure a better long-term outlook.

Visit link:
Osteoarthritis: Symptoms, Causes, and Treatments - Verywell Health

Owen Warner visits hair clinic to ‘prevent going down route of Vin Diesel and Dwayne Johnson’ – The Mirror

Hollyoaks actor Owen , who portrays Romeo Nightingale in the Channel 4soap opera, travelled to the hair clinic in Hale, Manchester after worrying about his 'receding' hairline

I'm A Celebrity... Get Me Out Of Here! finalist Owen Warner has joked he "doesnt want to go down the route of Hollywood celebrities like Vin Diesel or Dwayne The Rock Johnson" after visiting the British Hair Clinic.

The 23-year-old became a fans' favourite on the popular ITV reality show when he came runner-up behind England Lioness Jill Scott as I'm A Celeb returned to the New South Wales jungle for the first time in three years due to coronavirus.

The Hollyoaks actor, who portrays Romeo Nightingale in the Channel 4 soap opera, travelled to the hair clinic in Hale, Manchester after worrying about his 'receding' hairline despite still having a full head of thick brown hair.

Speaking in a video posted on British Hair Clinic's Instagram page, which has more than 12,400 followers, Owen said: "Hair transplant is a big process to go through and I thought why not prevent it for as long as I can, make my head healthy, thick hair on the top of my head, just prevention really.

"It's like stopping something before it could possibly go a certain way."

He added that he "doesnt want to go down the route of Hollywood celebrities like Vin Diesel or Dwayne The Rock Johnson who are completely bald, it suits them but not sure it would work for me!"

From secret feuds and sexy scandals to the biggest showbiz headlines - we're serving up a daily dose of gossip.

Get the inside scoop on all your favourite celebs with our daily newsletter delivered straight to your inbox for free.

You can sign up here.

Owen underwent Platelet Rich Plasma (PRP) injections which can effectively prevent hair loss and promote new hair growth.

He joins a host of celebrities who have used British Hair Clinic to manage their hair issues. Former England rugby union captain Dylan Hartley, boxer Conor Benn and reality TV stars such as Towie's Kirk Norcross have all had treatment done at the clinic including hair transplants.

Owen's ex-girlfriend and former Hollyoaks star Stephanie Davis underwent a female hair transplant at the British Hair Clinic.

He continued: "I need to keep the hair thinning on hold. Im young and as an actor who plays certain roles so I need to maintain a youthful appearance.

"Im conscious about my hair just as I am about my general health, better to be healthy and have a good head of hair than to be unhealthy and bald, especially if health and hair can be maintained.

"Its important to be proactive as an actor and not let your appearance deteriorate as essentially our talent and looks help us get the roles we need."

*Follow Mirror Celebs on Snapchat , Instagram , Twitter and Facebook .

More here:
Owen Warner visits hair clinic to 'prevent going down route of Vin Diesel and Dwayne Johnson' - The Mirror

Osteoarthritis of the knee: How Temple Health is helping ease knee … – WPVI-TV

PHILADELPHIA (WPVI) -- For millions of people, arthritis of the knees causes frequent pain and limits their lives.

Yet they're often afraid of joint replacement surgery.

A Philadelphia man says getting over his reservations put him back on the road again.

Lester Frisby of Juniata Park admits he was a crazy kid.

"We used to jump out of the second flood window onto mattresses," Frisby recalls.

And his knees paid the price.

"The body doesn't forget what you put it through," he notes.

Dr. Mark Desmond, a Temple Health orthopaedic surgeon, says osteoarthritis develops when cartilage - the cushion between the upper and lower leg bones - gets damaged over time.

"And sometimes it gets so worn, that there's none left, and there's only bone rubbing on bone, which can be very painful," Dr. Desmond says.

"My pain level was easy 7 to 10 every day," Frisby says.

Dr. Desmond says the first treatments for knee osteoarthritis try to make people comfortable with what they have.

Losing weight, over-the-counter medications, braces, and changing exercises can cut stress on the knees.

"Instead of running, consider cycling. If you can swim, swimming is great exercise. It's low-impact, no-impact. There are ellipticals and other knee-sparing exercises," says Dr. Desmond.

Physical therapy can help, too.

"To strengthen the muscles around the joint can really actually decrease some of the abnormal forces," he notes.

Injections are usually the next step: cortisone or other steroids first, later a gel lubricant that mimics the cushioning effect of cartilage.

Studies show three treatments of PRP, platelet-rich plasma, often ease pain.

When 30 years of knee injections stopped working, his doctor said knee replacement was the only option left.

"You can live the rest of your life always having trouble with your knees or you can live the rest of your 70s, 80s, and 90s pain-free," Frisby recalls his doctor saying.

Dr. Desmond eased Frisby's worries about surgery.

"He made me feel so good, that the first thing that came outta my mouth was - how soon can we do it?" he says with a broad smile

Hours after having both knees replaced last October, Frisby wasn't just up, he was walking around the hospital, finally free of that grinding pain.

"They had to slow me down," he laughs.

And he waves off reservations some have on getting two knees at once. "One surgery, one rehab."

Frisby is back to his job driving rideshare and delivering auto parts.

And boy, is he ready for spring!

"I can't wait to get on my motorcycle. I haven't been on it for 3 years," he says happily.

"The majority of people are very happy with their results," adds Dr. Desmond.

Dr. Desmond says acupuncture gave his mother three years of pain relief before she needed a joint replacement. So he encourages patients to check out all the avenues they can.

Visit link:
Osteoarthritis of the knee: How Temple Health is helping ease knee ... - WPVI-TV

New Haven doctor uses healing injections so patients can avoid surgery – WTNH.com

NEW HAVEN, Conn. (WTNH) Every year, many people undergo surgery for problems with their joints.

Paul Gebauer was almost one of them. Gebauer, a 60-year-old from Clinton, was in extreme pain from an issue involving his shoulder.

I was diagnosed with a torn tendon in my shoulder, he said.

Thanks to his wifes research, he found New Haven orthopaedic surgeon Phillip Luchini of Luchini Orthopaedic, who performs in in-office procedure to relieve joint pain.

The procedure uses something called platelet rich plasma or PRP. It is not like a cortisone shot which just eases pain. PRP actually uses bloods own plasma to heal from within.

A patients blood is put into a centrifuge, which separates out the plasma. The plasma is then injected into the patients trouble area under ultrasound guidance.

The platelets release their growth factors, and then that jumpstarts the natural healing process in the body, Luchini said.

Areas that can be treated with PRP include shoulders, elbows, hips, wrists, knees, ankles and arthritic joints.

This is another modality we can use to avoid surgical treatment in many cases, Luchini said.

It worked in one try for Paul, who was in so much pain he was ready to undergo surgery if needed.

It was a little sore for like a day or two, but then over a matter of like a week or so, it was like holy cow, its all better, Gebauer said.

He can now do the simple things again that he once took for granted including playing tennis with his daughter.

The procedure itself is not covered by insurance. Costs start at $500. It does not work on everyone, and some people need multiple treatments.

See more here:
New Haven doctor uses healing injections so patients can avoid surgery - WTNH.com